About InSitu Biologics
InSitu Biologics is a private company based in Oakdale, Minnesota. It has reported $25,206,850 raised in six offerings on Form D since November 2017. Its chief executive is Daniel Halpern.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Aug 10, 2026amended Oct 14, 2026 | $1,250,000of $3.3M target | 1 | $1.2M | Debt, Options, Convertible Promissory NoteRule 506(b) | Form D/A ↗1 earlier filing |
| Nov 13, 2025 | Dec 18, 2025 | $3,950,000of $8.0M target | 29 | $136K | EquityRule 506(b) | Form D ↗ |
| Oct 14, 2022 | Dec 29, 2023amended Nov 10, 2026 | $15,037,850of $19.8M target | 27 | $556K | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 29, 2020 | Feb 25, 2021 | $4,969,000of $5.5M target | 22 | $225K | Debt, Options, Securities on exerciseRule 506(c) | Form D ↗ |
| Not yet | Dec 7, 2017amended Mar 7, 2018 | $0of $1.0M target | 0 | — | EquityRule 506(c) | Form D/A ↗1 earlier filing |
| Not yet | Nov 22, 2017 | $0of $1.0M target | 0 | — | EquityRule 506(c) | Form D ↗ |
| Total, six offerings | $25,206,850 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on InSitu Biologics's Form D filed Oct 14, 2026.
Earlier filings also listed Kevin Bassett (president and ceo, director, last listed Feb 2021), Kevin Barrett (executive officer, last listed Feb 2021), Kay Warnott (executive officer, last listed Feb 2021), James Knapp (director, last listed Feb 2021), Buzz Benson (director, last listed Feb 2021), Andy LaFrence (director, last listed Feb 2021) and Jim Segermark (executive officer, last listed Mar 2018).